Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 06/20/25 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
|
11 | |
| 06/12/25 | 8-K | Current report |
|
   |
77 |
| 06/12/25 | 424B5 | Prospectus [Rule 424(b)(5)] |
|
86 | |
| 06/11/25 | 424B5 | Prospectus [Rule 424(b)(5)] |
|
86 | |
| 06/11/25 | 8-K | Current report |
|
|
48 |
| 06/10/25 | 8-K | Current report |
|
|
5 |
| 06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 06/09/25 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
